Medicare at Age 50

NCPA: The 50-year old Medicare program is not aging well; and that’s not good news for seniors, according to a new report by National Center for Policy Analysis Senior Fellow Devon Herrick. The report identifies three factors driving Medicare towards bankruptcy.

What Public Policies Are Hurting Minorities ?

Chairman Cruz and members of the committee, thank you for the opportunity to submit written comments about the challenges facing low-income individuals and families in today’s economy.  I am Pamela …

3 Medicare Reforms That Could Keep Seniors Healthier, Wealthier

NCPA: Empowering seniors to take control of their own health spending and rewarding the doctors who coordinate patients’ care, as well as the providers that reduce patients’ costs and improve the quality of their treatment, could vastly improve the health of seniors on Medicare, according to a new report by National Center for Policy Analysis Senior Fellow Devon Herrick.

Hillary on drugs: Bad prescription

Washington Examiner: “Clinton’s solution to reducing high drug prices is to ban direct-to-consumer advertising, take away advertising tax deductions, and force drug companies to inefficiently manage funds,” says NCPA Senior Fellow John R. Graham in a Washington Examiner commentary. “She ignores the needless FDA red tape and the necessity to streamline the drug review and approval.”

The Suffering of Iran’s Victims will Endure

Townhall: The ink is not even dry on Obama’s ill-conceived executive agreement with Iran and already observers have found potentially unlawful stipulations baked into the agreement. A predictable development, to be sure, but it seems last minute. The administration has already ignored other judicial pronouncements through the course of negotiations without much fanfare. As the debate now inevitably plunges into squabbles over illegalities, it is time to address the outstanding judgment still haunting grieving victims of Iran’s terrorism.

Should Drug Patents Apply in Poor Countries?

Real Clear Policy: In light of the World Trade Organization’s upcoming discussion of current patent exemptions, NCPA Senior Fellow Thomas A. Hemphill discusses the intellectual property benefits and concerns associated with drug patents in least developed countries in a Real Clear Policy commentary.